Viva Biotech (HKG:1873) expects an attributable profit of between 150 million yuan and 180 million yuan for the year 2024, against an attributable loss of 116.1 million yuan a year prior, a Thursday filing with the Hong Kong bourse said.
The biotechnology firm's adjusted non-IFRS attributable profit will fall between 240 million yuan and 270 million yuan for the year, mainly attributable to a substantial growth recovery of the contract research organization business, higher operating margins, and investment gains.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。